Pfizer Maraviroc: Last Entry Inhibitor In Pivotal Trials For Treatment-Naïve HIV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s maraviroc is the only HIV entry inhibitor remaining in late-stage trials for front-line treatment of antiretroviral-naïve HIV patients.